EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

MiR-143-3p serves as a novel biomarker for diabetic cardiomyopathy and is involved in regulating high glucose-induced cardiomyocyte injury

Zhengnan Zhang, Suyun Wang, Liping Zhu, Yang Bian iD, Jing Zhao

Diabetes & Vascular Disease Research · 2026-07 · 23 (4)

DOI: 10.1177/14791641261454501 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes & Vascular Disease Research, online erschienen am 22.07.2026. Verfasst von Zhengnan Zhang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Cardiovascular Department, Geriatric Hospital Affiliated to Wuhan University of Science and Technology, Wuhan, China. Hauptthemen laut MEDLINE: Diabetic Cardiomyopathies, MicroRNAs, Myocytes, Cardiac, Glucose. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

This work aimed to verify the value of miR-143-3p in diabetic cardiomyopathy (DCM).

Methods

The ROC curve, correlation analysis, and multivariate Logistic regression analysis assessed the diagnostic value, association with DCM, and DCM risk factors. Bioinformatic analysis predicted the downstream targets of miR-143-3p. Dula-luciferase reporter assay validated the interaction between miR-143-3p and ERBB3. In vitro high glucose (HG)-stimulated cardiomyocyte (AC16) injury was employed to clarify the mechanism of the miR-143-3p/ERBB3 axis in DCM.

Results

Upregulation of miR-143-3p was observed in the DM group and further elevated in the DCM group compared with healthy individuals. The upregulated miR-143-3p expression distinguished subjects with DM from healthy individuals and diagnosed subjects with DCM from DM. MiR-143-3p expression was associated with blood glucose, myocardial injury, and cardiac function of DCM, and predicted the risk for DCM development. In vitro, the inhibition of miR-143-3p attenuated HG-induced AC16 cell injury through improving cell proliferation, suppressing apoptosis, inflammation, oxidative stress, and the release of myocardial enzymes by upregulating the ERBB3 expression.

Conclusions

Upregulation of miR-143-3p showed a diagnostic potential for DCM and predicted the progression of DCM. In vitro, miR-143-3p promoted HG-induced cardiomyocyte injury by targeting ERBB3, which might provide novel insights for DCM clinical management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetic CardiomyopathiesMicroRNAsMyocytes, CardiacGlucoseHumansApoptosisSignal TransductionReceptor, ErbB-3Oxidative StressCell ProliferationMaleCase-Control StudiesFemaleMiddle AgedAnimalsCell LineBlood Glucose

Stichwörter der Autor:innen

ERBB3cardiomyocyte injurydiabetic cardiomyopathymiR-143-3ptype 2 diabetes mellitus

Substanzen

MicroRNAsMIRN143 microRNA, humanGlucoseReceptor, ErbB-3ERBB3 protein, humanBlood Glucose

Autor:innen und Institutionen

  • Cardiovascular Department, Geriatric Hospital Affiliated to Wuhan University of Science and Technology, Wuhan, China.
  • Cardiology Department, Wuxi Hospital of Traditional Chinese Medicine Wuxi, China.
  • Department of Endocrinology, Huaihe Hospital of Henan University, Kaifeng, China.
  • Department of Cardiology, Baoji Hospital of Traditional Chinese Medicine, Baoji, China.
  • Department of Emergency, Taikang Tongji (Wuhan) Hospital, Wuhan, China.

ORCID-Profile: Yang Bian

Zitieren

APA

Zhang, Z., Wang, S., Zhu, L., Bian, Y., & Zhao, J. (2026). MiR-143-3p serves as a novel biomarker for diabetic cardiomyopathy and is involved in regulating high glucose-induced cardiomyocyte injury. Diabetes & Vascular Disease Research, 23(4). https://doi.org/10.1177/14791641261454501

Vancouver

Zhang Z, Wang S, Zhu L, Bian Y, Zhao J. MiR-143-3p serves as a novel biomarker for diabetic cardiomyopathy and is involved in regulating high glucose-induced cardiomyocyte injury. Diabetes & Vascular Disease Research. 2026;23(4). doi:10.1177/14791641261454501

BibTeX
@article{Zhang2026,
  author = {Zhang, Zhengnan and Wang, Suyun and Zhu, Liping and Bian, Yang and Zhao, Jing},
  title = {MiR-143-3p serves as a novel biomarker for diabetic cardiomyopathy and is involved in regulating high glucose-induced cardiomyocyte injury},
  journal = {Diabetes & Vascular Disease Research},
  year = {2026},
  volume = {23},
  number = {4},
  doi = {10.1177/14791641261454501}
}
Kostenlos starten →